Publikationen in Zusammenarbeit mit Forschern von Novartis (Sweden) (9)

2024

  1. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

    Lung Cancer, Vol. 197

2023

  1. Unveiling chronic spontaneous urticaria pathophysiology through systems biology

    Journal of Allergy and Clinical Immunology, Vol. 151, Núm. 4, pp. 1005-1014

2022

  1. EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)

    Future oncology (London, England), Vol. 18, Núm. 31, pp. 3481-3492

2019

  1. Effectiveness of dabrafenib in the treatment of patients with braf v600-mutated metastatic melanoma in a named patient program

    Melanoma Research, Vol. 29, Núm. 5, pp. 527-532

2018

  1. Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 6, Núm. 4, pp. 1191-1197.e5

2016

  1. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria

    Journal of Allergy and Clinical Immunology, Vol. 137, Núm. 2, pp. 474-481

2015

  1. Patterns of HER2 gene amplification and response to anti-HER2 therapies

    PLoS ONE, Vol. 10, Núm. 6

2013

  1. Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2

    Clinical Breast Cancer, Vol. 13, Núm. 6, pp. 421-432.e8

2005

  1. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: Results of a pilot randomized controlled clinical trial

    Journal of Hepatology, Vol. 43, Núm. 4, pp. 630-636